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AbstrAct
Introduction. Trigeminal neuralgia (TN) is one of the most common neurological diseases involving the orofacial region. 
It affects mainly the older population, usually after the age of 60, and more commonlywomen. It involves the fifth cra-
nial nerve and manifests as paroxysmal, unilateral, severe, shock-like or knife-like pain of from a second to two minutes’ 
duration. Usually pain attacks arise spontaneously, but they can also be precipitated by triggers such as cold weather, 
brushing teeth or shaving. The ICHD-3 classification divides TN into classical, secondary and idiopathic. Current treat-
ment includes pharmacological and surgical methods. Anticonvulsants, such as carbamazepine and oxcarbazepine, are 
the first line therapy. Microvascular decompression is the most common and most effective way to treat TN surgically. 
However, none of these methods is free from complications. Moreover, 25–50% of patients became refractory to drug 
therapy. Some studies have shown that a new therapy that uses a Botulinum toxin type A can be a safe and effective 
way to treat trigeminal neuralgia.
Methods. Literature from the PubMed base and the Main Medical Library from the last 18 years was analysed. Forty-three items 
were obtained; after verification, seven articles were included.
Aim of the study. To look at current guidelines about treating trigeminal neuralgia with Botulinum Toxin type A in patients who 
are refractory to drug therapy or who do not want to undergo surgical treatment.
conclusion. BoNT-A therapy is a safe and effective method of treating trigeminal neuralgia.
Key words: trigeminal neuralgia, neuropathic pain, trigeminal nerve, botulinum toxin 
(Neurol Neurochir Pol 2019; 53 (5): 327–334)
Introduction
Trigeminal neuralgia (TN) is one of the most common neu-
rological pains involving the orofacial region. Epidemiological 
studies have shown that approximately 4 to 28.9/100,000 persons 
worldwide experience TN. It affects mainly the older population, 
usually after the age of 60, and is more common in women than 
in men [1, 2]. It involves the fifth cranial nerve and manifests 
as paroxysmal, unilateral, severe, shock-like or knife-like pain 
lasting between a second and two minutes. Usually pain attacks 
arise spontaneously, but they can also be precipitated by triggers 
such as cold weather, brushing teeth or shaving [3].
IHS Classification ICHD-3 divides TN into classical, 
secondary and idiopathic. 
There are two types of classical TN: purely paroxysmal 
(without persistent background facial pain); and with con-
comitant continuous pain (with persistent background facial 
pain). Classical TN is mainly caused by vascular compression. 
The classification distinguishes three types of secondary 
TN: TN attributed to multiple sclerosis, TN attributed to 
a space-occupying lesion (e.g. brain tumour) and TN attribu-
ted to a cause other than those described above. 
Idiopathic TN divides in two: purely paroxysmal and TN 
with concomitant continuous pain [4, 5]
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the study was to estimate the degree of pain relief, which was 
based on the visual analogue scale (VAS), plus the frequency 
of pain attacks per day. Patients with a ≥ 50% reduction in 
mean VAS score at the endpoint of the study were considered 
to be responders. Out of 42 patients, 21 and 19 patients from 
the BoNT-A and placebo groups, respectively, completed the 
study. Fifteen (68.18%) patients from the BoNT-A group and 
three (15.00%) from the placebo group responded to treat-
ment. Moreover, 17 (77.27%) patients from the BoNT-A and 
four (20.00%) patients from the placebo group reported 
a significant or very significant improvement in symptoms. 
Attack frequency was also reduced in the BoNT-A patients. All 
of these differences were found to be statistically significant. 
The authors concluded that Botulinum toxin type-A may be 
a novel, safe and efficient strategy for trigeminal neuralgia 
treatment.
Zúñiga et al. [17] treated 36 patients with a subcutaneous 
injections that contained 1 ml of 0.9% saline or 50 U of BO-
TOX, depending on the group of patients. Cases with third 
branch of involved also received either 10 U of BOTOX or pla-
cebo into the masseter muscle. This randomised, double-blind, 
placebo-controlled study was performed to evaluate the tole-
rability, safety and efficacy of BoNT-A treatment in classical 
TN. Patients were assigned to two groups, 20 of them to receive 
BOTOX, and 16 to receive a placebo. Drugs were administered 
in various sites, 1 cm apart from one another, according to the 
path of the involved branch. This was always performed by 
the same physician using the same technique. The aim of the 
study was to evaluate the reduction in pain severity and attack 
frequency. Pain was assessed with the visual analogue scale 
(VAS). All patients completed the study. The initial mean VAS 
scores was 8.85 and 8.19 for BoNT-A and placebo patients, 
respectively. One month after intervention, the differences in 
mean VAS values in both groups were compared, and reported 
as nonsignificant (VAS 5.05 vs 6.06 in BoNT-A and placebo 
group, respectively). A significant decrease in the number of 
paroxysms was observed among the patients treated with BO-
TOX. Two months after the injections, a significant reduction 
in mean VAS scores in the BoNT-A group was observed and 
this was maintained until the end of the three-month follow-
-up period. At the endpoint of the study, the mean VAS score 
for patients treated with BOTOX was 4.75, and 6.94 for those 
treated with a placebo. Also, the frequency of attacks was sig-
nificantly lower than at the beginning in the BoNT-A group 
(29.1 vs 7.1 paroxysms per day). These results were statistically 
significant. The authors concluded that Botulinum toxin type 
A is useful in acute treatment of classical TN, and when added 
to current drug therapy may cause a significant decrease in 
pain expression. Eighteen patients completed the study.
Shehata et al. [18] carried out a randomised, double-blind, 
placebo-controlled study.  They treated 20 patients with intrac-
table idiopathic TN, which was defined as a failure to achieve 
50% reduction in pain intensity (quantified by VAS) and/or pa-
roxysm frequency during the previous three months. The aim 
TN can be treated pharmacologically and non-phar-
macologically. Anticonvulsants such as carbamazepine and 
oxcarbazepine are the first-line therapy in patients with tri-
geminal neuralgia. Unfortunately, about 25–50% of patients 
become refractory to drug therapy and require higher doses 
during the therapy. Also, the risk of side effects increases with 
prolonged use. Patients who are refractory to drugs or who 
do not tolerate side effects may undergo surgical procedures, 
i.e. microvascular decompression, gamma-knife radiosurgery, 
partial sensory rhizotomy, and percutaneous radiofrequency 
thermocoagulation, which comprise the second-line therapy 
in TN. But all of these surgical methods are associated with 
multiple postoperative complications [6, 7]
Some studies have shown that there is a new therapy 
that uses a Botulinum toxin type A (BTX-A or BoNT-A), 
a natural neurotoxin derived from the bacterium Clostridium 
botulinum [8, 9]. It inhibits the release of acetylcholine at 
neuromuscular junctions, causing relaxation of the muscle as 
well as pain-modulating neurotransmitters, which is why it 
has been studied for its effectiveness in treating neuropathic 
pain [10]. BTX-A is commonly used in cosmetic surgery, and 
in recent years also in medicine to manage conditions such 
as blepharospasm, hemifacial spasm, chronic migraine, post-
-stroke spasticity and many other types of headache [11–15].
The present review was undertaken to give an overview of 
the available evidence that BoNT-A has a therapeutic effect 
on TN.
Methods
The literature from the PubMed base and the Main Me-
dical Library from the last 18 years was analysed. Key words 
included: trigeminal neuralgia, botulinum toxin, neuropathic 
pain, and trigeminal nerve. Forty-three items were obtained; 
after verification, seven articles were reviewed with attention 
to the efficacy and safety of Botulinum toxin Type A therapy in 
trigeminal neuralgia. The works were set out in a tabular form 
considering the number of patients and the BoNT-A therapy 
used to reduce the pain in TN patients: this is Table 1. Different 
types of toxin which were used in the evaluated studies are 
set out in Table 2.
Results
Wu et al. [16] performed a randomised, double-blind, 
placebo-controlled study to investigate the efficacy, safety 
and tolerability of BoNT-A  in the treatment of trigeminal 
neuralgia. A total of 42 patients were randomly divided into 
two groups: 22 in the BoNT-A group and 20 in the placebo 
group. They were followed-up over 12 weeks. Intradermal 
and/or submucosal injections were performed along the area 
of pain distribution. A total of 75 U of BoNT-A were given 
into 15 injection sites. Similarly, patients from the placebo 
group received an equal volume of 0.9% saline. The object of 
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table 2. Types of botulinum toxin
Author, title, country, year type of botulinum toxin Dilution
Wu et al., 




(Onabotulinumtoxin type A); 
100 U of Clostridium botulinum type A neurotoxin complex, 5mg gelatin, 25mg 
dextran, and 25mg saccharose (Lanzhou Biological Products Institute, China)
100 U of BoNT-A in 2 ml 0.9% 
saline
Zủñiga et al.,  




100 U of BoNT-A in 2 ml 0.9% 
saline
Shehata et al., 




100 U of BoNT-A in 2 ml 0.9% 
saline
Li et al., 




(Onabotulinumtoxin type A); 
100 U of Clostridium botulinum type A neurotoxin complex, 5mg gelatin, 25mg 
dextran, and 25mg saccharose (Lanzhou Biological Products Institute, China)
100 U of BoNT-A in 2 ml 0.9% 
saline
Zhang et al., 
Two doses of botulinum [...]; 
China, 2014
HengLi®  
(Onabotulinumtoxin type A); 
100 U of Clostridium botulinum type A neurotoxin complex, 5mg gelatin, 25mg 
dextran, and 25mg saccharose (Lanzhou Biological Products Institute, China)
Depending on group: 
25 U of BoNT-A in 1 ml 0.9% 
saline 
or 
75 U of BoNT-A in 1 ml 0.9% 
saline
Zhang et al., 




(Onabotulinumtoxin type A); 
100 U of Clostridium botulinum type A neurotoxin complex, 5mg gelatin, 25mg 
dextran, and 25mg saccharose (Lanzhou Biological Products Institute, China)
100 U of BoNT-A in 2 ml 0.9% 
saline
Liu et al., 




(Onabotulinumtoxin type A); 
100 U of Clostridium botulinum type A neurotoxin complex, 5mg gelatin, 25mg 
dextran, and 25mg saccharose (Lanzhou Biological Products Institute, China)
100 U of BoNT-A in 4 ml 0.9% 
saline
of the study was to evaluate the efficacy, safety and tolerability 
of BoNT-A in patients who were refractory to first-line drug 
therapy. Patients were randomised into either the BoNT-A or 
the placebo group, 10 subjects in each group. Subcutaneous 
injections were performed using the ‘follow the pain’ method. 
Also, botulinum toxin was injected into the posterior part of 
the masseter muscle if the mandibular root of the trigeminal 
nerve was affected. Each injection site received 5 U of BoNT-
-A. The overall doses ranged from 40 U to 60 U (mean ± SD 
of 48 ± 5.87 U). All of the patients completed the 12-week 
study period. Significant reductions in both efficacy measures, 
i.e. pain VAS scores and attack frequency, were observed in 
week 2 and were maintained over the follow-up period. At the 
endpoint, mean VAS scores were decreased by 6.5 and 0.3 for 
BoNT-A and placebo, respectively. The authors concluded that 
subcutaneous BoNT-A injections can be an effective treatment 
option in cases with intractable TN.
Several studies were evaluated for the purpose of assessing 
the efficacy of different doses and methods in botulinum toxin 
type A therapy. Li et al. [19] performed a study to investigate 
the long-term effects and safety of BoNT-A in TN treatment. 
Eighty-eight subjects with one-branch classical TN were in-
cluded. Patients were asked to report the expression of pain 
(measured by VAS) and attack frequency. A patient’s overall 
response to treatment was evaluated over the course of 
a 14-month follow-up period. The main goal of the study was 
to estimate the influence of different doses on the therapeutic 
effect of BoNT-A. Injections were given in the trigger areas at 
15–20 points (0.5 cm depth, 15 mm separation, 2.5–5 U per 
point). Forty-three cases received ≤ 50 U, 32 cases received 
from 50 U to 100 U, and 13 cases received ≥ 100 U of BoNT-A. 
Minimal and maximal doses were 25 U and 170 U, respectively. 
All 88 patients showed an improvement in symptoms within 
two weeks. At two months, the percentage of patients in whom 
treatment was effective had reached 100%. After three months, 
the effectiveness of BoNT-A therapy decreased gradually. The 
authors concluded that there were no significant differences 
in effectiveness of treatment or attack frequency between the 
different dose groups at identical time points between oneand 
14 months. Moreover, the maintenance of therapeutic effect 
was not related to different dosages, but was related to the 
reduction of VAS score after the first set of injections.
Zhang et al. [20] included 84 patients into a randomised, 
double-blind, placebo-controlled study to assess the efficacy 
and safety of two different doses of BoNT-A in TN therapy. All 
patients suffered from classical TN. Patients were randomly 
divided into three groups: placebo (n = 28), BoNT-A25U (n = 
27), and BoNT-A75U (n = 29), and were followed-up during 
an 8-week period. Patients received placebo or BoNT-A via 
intradermal and/or submucosal injections, which were guided 
by the individual patient’s experience of pain. These doses were 
injected into 20 sites. The purpose of the study was to define 
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an effective dose of BoNT-A. Pain severity, attack frequency, 
overall response to treatment, and proportion of responders (≥ 
50% reduction in mean pain score from baseline to endpoint) 
were assessed during the study. 32.1% of patients from the 
placebo group, 70.4% of patients from the BoNT-A25U group, 
and 86.2% of patients from the BoNT-A75U group responded 
to treatment. The VAS scores in the BoNT-A patients reduced 
significantly one week after the first injections, and were main-
tained until the end of the study. Pain symptoms vere much or 
very much improved in 66.7% and 75.9% of patients from the 
25 U and the 75 U group, respectively. Only 32.1% of patients 
who received the placebo reported the same improvement as 
in the BoNT-A groups. These results showed that both doses 
were effective in TN treatment, but there were no significant 
differences between the groups. Thus, the authors concluded 
that 25 U and 75 U doses are similar in efficacy over a short 
period of time.
Zhang et al. [21] compared two different methods of 
BoNT-A  administration: single-dose and repeated-dose 
therapy. They conducted a open-label trial which included 
100 patients with classical TN. Fifty patients received an in-
tradermal and/or a submucosal single injection of 70–100 U of 
BoNT-A at the site of pain. The other 50 patients received 
two sets of injections using the aforesaid method. The initial 
injection contained 50–70 U of BoNT-A. Two weeks later, 
another set of injections was given with an equal volume 
of BoNT-A. The drug was given in 15–25 sites, with 0.1 cm 
depth and 15 mm separation between sites. Each point recei-
ved 1.25–5 U of BoNT-A. Every patient was interviewed for 
severity of pain (VAS score) and rate of TN occurrence. After 
a 6-month follow-up, 44 patients from the single-dose group 
and 37 patients from the repeated-dose group completed the 
study. Mean VAS scores at the baseline and the endpoint for 
the single-dose method were 8.26 ± 1.68 and 3.02 ± 3.29, re-
spectively. In the repeated-dose method, mean VAS score at the 
baseline was 7.98 ± 1.60, which had decreased by the endpoint 
to 4.32 ± 3.61. In both groups, VAS scores and drug response 
rates were not significantly different. However, the duration of 
efficacy in those patients who underwent single-dose therapy 
was significantly longer than that of the repeated-dose patients. 
The authors conluded that repeated dosing has no advantage 
over single dosing of BoNT-A, and that single dosing may be 
the best choice in TN therapy. Multiple injections should be 
considered for patients who respond poorly to the first set 
of injections. Dosing should be adjusted for the individual 
patient.
A new study, which assessed the efficacy and safety of 
BoNT-A for treating idiopathic TN in patients ≥ 80 y.o., ap-
peared last year. Liu et al. [22] selected 43 patients who were 
divided into two groups: ≥80 years old (n = 14) and < 60 ye-
ars old (n = 29). Prior to treatment, the median pain scores 
(measured by VAS) in both older and younger patients were 
8.5 and 8.0, respectively. BoNT-A was given in similar doses in 
all groups. Total doses ranged from 30 U to 200 U (mean ± SD 
of 71.80 ± 33.14 U) and from 45 U to 150 U (91.30 ± 25.64 U) 
in the < 60 y.o. and the ≥ 80 y.o. patients, respectively. One 
month after treatment, median VAS scores in older (4.5) and 
younger (4.0) were significantly lower than the corresponding 
baseline values. The authors proved that BoNT-A injections 
are an effective and safe therapy for idiopathic TN in elderly 
patients at doses similar to those used in younger patients.
The use of BoNT-a in the treatment of TN is confirmed not 
only by the abovementioned studies, but also by many other 
publications that were not included in our review.
Discussion
TN is characterised by episodes of spontaneous pain or 
a triggered intense facial pain that lasts for a short duration 
[23]. According to the current guidelines of the American 
Academy of Neurology and the European Federation of Neu-
rological Societies (AAN-EFNS), carbamazepine (CBZ) and 
oxcarbazepine are recommended as first-line drugs for treating 
patients with trigeminal neuralgia. Drugs such as baclofen, 
lamotrigine, phenytoin, topiramate and pimozide may also be 
considered [24]. However, high dosages and the long-term use 
of CBZ are not free from complications. These mainly take the 
form of eliciting drowsiness, dizziness, diplopia, leukopenia, 
hyponatremia and disturbances of the vitamin D metabolism 
[25]. The most common adverse effects of oxcarbazepine are 
usually related to the central nervous system and digestive sy-
stem, including fatigue, drowsiness, diplopia, dizziness, nausea, 
vomiting and rashes [26]. If the pharmacological treatment 
fails, there are surgical options that can alleviate the pain in 
TN, e.g. microvascular decompression, percutaneous radiofre-
quency rhizotomy, percutaneous glycerol rhizotomy, balloon 
compression and gamma knife radiosurgery. Microvascular 
decompression is the most effective treatment for classical 
TN: it may provide initial pain control in the range of 80.3% 
to 96.0%. However, this procedure is not as safe as it might 
seem to be. The most common postoperative complications 
are an up to 22% rate of trigeminal nerve deficit, less than 11% 
of facial weakness, about 7% of hearing loss, and sometimes 
aseptic meningitis, cerebrospinal fluid leakage and anaesthesia 
dolorosa [27]. Based on the this knowledge, it is safe to say that 
there is a need to find a new treatment for TN patients. 
The use of BTX-A in trigeminal neuralgia was first repor-
ted in 2002 by Michaeli et al. who successfully treated a patient 
with a hemifacial spasm associated with TN [28]. The main 
action of BoNT-A is to inhibit the release of acetylcholine 
at the neuromuscular junction. The mechanism of potential 
analgesic effect of BoNT-A is still unclear. It can inhibit the 
peripheral sensitisation of nociceptive fibres, hence reducing 
central sensitisation by inhibiting the release of glutamate 
and substance P. Moreover, BTX-A significantly reduces the 
high expression of TRPA1, TRPV1 and TRPV2 in the spi-
nal trigeminal nucleus, what can directly modulate central 
sensitisation and exerts an antinociceptive function [29, 30]. 
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A new study performed by Yang et al. revealed that the antino-
ciceptive effects of BoNT-A are connected with the inhibition 
of upregulated Nav isoform 1.7 in Gasserian ganglion [31]. 
More research needs to be done to thoroughly understand 
how BoNT-A relieves the pain in TN.
The studies included in our review promote the use of 
BoNT-A. This topic enjoys great interest in China, and there-
fore most of the articles chosen for this review are publications 
from that particular country. However, it should be noted 
that attempts to treat trigeminal neuralgia with BoNT-A have 
also been undertaken in other countries, e.g. Norway, USA, 
Germany, Iran and Malaysia [32–37].
The percentage of patients who have responded to tre-
atment has ranged from 68% to as much as 100%. Attack 
frequency and pain severity were predominantly reduced one 
week and two weeks after injections, respectively. Treatment 
was effective for about 3-6 months. The most commonly used 
injection method was multiple intradermal and/or subcuta-
neous injections in the painful area. However, other methods, 
such as injections into the masseter muscle or injections above 
and below the zygomatic arch, should also be considered 
[38–40]. Doses of BoNT-A have been determined empirically 
and ranged from 25U to 200 U. In addition, this therapy is not 
free from complications. All of the reported adverse reactions 
(e.g. facial asymmetry, oedema, pain, haematoma) were mild 
and transient.
Despite the above-mentioned information, which 
highlights the positive effect of BoNT-A  treatment, a  few 
points need to be discussed. 
The first question is the duration of patient follow-up. Wu 
et al., Zúñiga et al. and Zhang et al. performed studies with 
follow-ups of eight or 12 weeks or three months. Such periods 
are too short to assess the long-term effects of BoNT-A in TN, 
especially in those studies that set out to compare the effects 
of different doses. Long-term trials are needed to correctly 
evaluate whether a high dose of BoNT-A has any advantages 
over lower doses.
Secondly, was the baseline therapy kept unchanged after 
BoNT-A  treatment? There was no information about the 
anticonvulsants that patients received after injections. In ad-
dition, each patient took different doses or medications before 
and during BoNT-A therapy, what may have played a role in 
reducing the primary endpoints, such as pain severity and 
attack frequency. What is more, Li et al. did not provide any 
information about the medicines their patients were taking. 
In Wu et al.’s trial, one patient changed his medications during 
the BoNT-A therapy. We suggest that doses and medications 
should be uniform so as to clearly assess the efficacy of a new 
treatment strategy.
Another problem is that follow-up visits have been carried 
out by some authors for much longer than one week. Liu et 
al. and Zuniga et al. estimated patient response to treatment 
every one or three months after BoNT-A administration, 
respectively. Such a long period of time made it impossible to 
detect the early disappearance of pain and any reduction in 
the number of paroxysms per day.
In the study performed by Shehata et al., the blind phase 
was not maintained after the first follow-up visit. Despite 
the correct method of randomisation and blinding, facial 
asymmetry occurred in some patients and led to failure in the 
blinded phase. For these reasons, the investigator’s impressions 
could be biased.
Liu et al. included only 14 patients aged 80 or older. For 
comparison, a group with patients younger than 60 years old 
compared 29 cases. This number of patients is not sufficient 
to evaluate whether older patients can receive the same doses 
as younger ones. A study with more elderly patients is needed.
Finally, Zakrzewska JM [41] reported that Wu et al.’s study 
is not a high-quality evidence of BoNT-A’s effectiveness in 
trigeminal neuralgia therapy. This is mainly because of too 
little information being provided about the blinding phase and 
insufficient measures regarding selection, which can capture 
all aspects of pain experience.
Conclusions
To conclude, this review suggested that Botulinum toxin 
Type A injections are a safe and effective treatment option for 
patients with trigeminal neuralgia, and may be offered before 
surgery or for those unwilling to undergo surgery or where 
drug treatment has failed. Despite the possibility of occurrence 
of transient and mild adverse reactions, it represents a propi-
tious risk-to-benefit ratio. However, future studies are necessa-
ry to determine the optimal dosages and injection schemes for 
BoNT-A treatment, the duration of therapeutic efficacy, and 
indications as to when repeated injections are needed.
Ethical approval was not necessary for the preparation of this 
article.
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